Loomis Sayles & CO L P Ultragenyx Pharmaceutical Inc. Transaction History

Loomis Sayles & CO L P

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$34.92 - $46.66 $2,339 - $3,126	67 Added 78.82%	152 $5,000
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $3,174 - $4,432	85 New	85 $4,000
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $8.59 Million - $10.9 Million	-238,194 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$42.5 - $63.11 $804,950 - $1.2 Million	18,940 Added 8.64%	238,194 $10.2 Million
Q2 2019 Aug 14, 2019	BUY	$54.93 - $74.36 $12 Million - $16.3 Million	219,254 New	219,254 $13.9 Million

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.01B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.